Company news
Puma Biotechnology Inc (NASDAQ:PBYI) news
Puma Biotechnology Inc news releases on 6ix. Latest, Oct 5, 2026: Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Press releases & updates
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
October 5, 2026
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
October 4, 2026
Puma Biotechnology Initiates ALISCA(R)-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
September 18, 2026
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
September 17, 2026
Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference
September 9, 2026
Puma Biotechnology Reports Inducement Awards under Nasdaq Listing Rule 5635(4)
September 4, 2026
Puma Biotechnology Reports Second Quarter 2026 Financial Results
August 6, 2026
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2026 Financial Results
July 23, 2026
Puma Biotechnology Reports First Quarter 2026 Financial Results
May 7, 2026
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results
April 23, 2026
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results
February 25, 2026
Puma Biotechnology to Present at TD Cowen’s 46th Annual Health Care Conference
February 23, 2026
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results
February 12, 2026
Rigel Appoints Michael P. Miller to the Board of Directors
February 3, 2026
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
January 7, 2026
Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)
December 22, 2025
Puma Biotechnology Reports Third Quarter 2025 Financial Results
November 6, 2025
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
October 23, 2025
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635c4
October 3, 2025
Puma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 2, 2025
Puma Biotechnology Reports Second Quarter Financial Results
August 7, 2025
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results
July 24, 2025
Puma Biotechnology Reports First Quarter Financial Results
May 8, 2025
Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients
April 30, 2025
Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025
April 28, 2025
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results
April 24, 2025
Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025
March 26, 2025
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
March 5, 2025
Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results
February 27, 2025
Puma Biotechnology to Present at TD Cowen’s 45th Annual Health Care Conference
February 26, 2025
Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation
December 22, 2024
Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
November 19, 2024
Puma Biotechnology Reports Third Quarter 2024 Financial Results
November 6, 2024
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
June 2, 2024
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
June 1, 2024
Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting
May 22, 2024
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
March 19, 2024
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
February 12, 2024
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
December 10, 2023
Puma Biotechnology Reports Third Quarter 2023 Financial Results
November 1, 2023
Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
October 13, 2023
Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
August 7, 2023
Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting
June 3, 2023
Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology
March 13, 2023
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
March 1, 2023
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
February 15, 2023
Puma Biotechnology Releases Updated Corporate Presentation
January 8, 2023
Puma Biotechnology Reports Third Quarter 2022 Financial Results
November 2, 2022
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
October 26, 2022